Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo

Health and Quality of Life Outcomes

Volumn 7, Issue , 2009, Pages

  Van Kerrebroeck, Philip E V ^a   Kelleher, Con J ^b   Coyne, Karin S ^c   Kopp, Zoe ^d   Brodsky, Marina ^d   Wang, Joseph T ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOLTERODINE; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; OVERACTIVE BLADDER; PATIENT MONITORING; QUALITY OF LIFE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SELF CONCEPT; TREATMENT DURATION; TREATMENT RESPONSE; URINE INCONTINENCE; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; HOSPITALIZATION; MEDICAL RECORD; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRE; URGE INCONTINENCE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BENZHYDRYL COMPOUNDS; CRESOLS; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; YOUNG ADULT;

EID: 62149152079     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-7-13     Document Type: Article

References (33)

1. Abrams P Artibani W Cardozo L Dmochowski R van Kerrebroeck P Sand P Reviewing the ICS 2002 Terminology Report: The Ongoing Debate Neurourol Urodyn 2006, 25:293. 10.1002/nau.20251
2. Abrams P Cardozo L Fall M Griffiths D Rosier P Ulmsten U Van Kerrebroeck P Victor A Wein A The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society Urology 2003, 61(1):37-49. 10.1016/ S0090-4295(02)02243-4 12559262
3. Stewart WF Van Rooyen JB Cundiff GW Abrams P Herzog AR Corey R Hunt TL Wein AJ Prevalence and burden of overactive bladder in the United States World J Urol 2003, 20(6):327-336. 12811491
4. Milsom I Abrams P Cardozo L Roberts RG Thuroff J Wein AJ How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 2001, 87(9):760-766. 10.1046/ j.1464-410x.2001.02228.x 11412210
5. Irwin DE Milsom I Hunskaar S Reilly K Kopp Z Herschorn S Coyne KS Kelleher C Hampel C Artibani W et al Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study Eur Urol 2006, 50:1306-1315. 10.1016/j.eururo.2006.09.019 17049716
6. Andersson KE Antimuscarinics for the treatment of overactive bladder Lancet Neurol 2004, 3(1):46-53. 10.1016/S1474-4422(03)00622-7 14693111
7. Leidy NK Revicki DA Geneste B Recommendations for evaluating the validity of quality of life claims for labeling and promotion Value Health 1999, 2:113-127. 10.1046/j.1524-4733.1999.02210.x 16674343
8. Reese PR Pleil AM Okano GJ Kelleher CJ Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder Qual Life Res 2003, 12(4):427-442. 10.1023/ A:1023422208910 12797715
9. Coyne KS Matza LS Kopp Z Abrams P The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder Eur Urol 2006, 49(6):1079-1086. 10.1016/ j.eururo.2006.01.007 16460875
10. Coyne K Revicki D Hunt T Corey R Stewart W Bentkover J Kurth H Abrams P Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q Qual Life Res 2002, 11(6):563-574. 10.1023/A:1016370925601 12206577
11. Liberman JN Hunt TL Stewart WF Wein A Zhou Z Herzog AR Lipton RB Diokno AC Health-related quality of life among adults with symptoms of overactive bladder: Results from a U.S. community-based survey Urology 2001, 57(6):1044-1050. 10.1016/S0090-4295(01)00986-4 11377301
12. Coyne KS Payne C Bhattacharyya SK Revicki DA Thompson C Corey R Hunt TL The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: Results from a national community survey Value Health 2004, 7(4):455-463. 10.1111/j.1524-4733.2004.74008.x 15449637
13. Coyne KS Zhou Z Thompson C Versi E The impact on health-related quality of life of stress, urge and mixed urinary incontinence BJU Int 2003, 92(7):731-735. 10.1046/j.1464-410X.2003.04463.x 14616456
14. Abrams P Kelleher C Lerr L Rogers R Overactive bladder significantly affects quality of life Am J Manag Care 2000, 6:S580-590. 11183901
15. Irwin DE Milsom I Kopp Z Abrams P Cardozo L Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries BJU Int 2006, 97(1):96-100. 10.1111/ j.1464-410X.2005.05889.x 16336336
16. Kelleher CJ Reese PR Pleil AM Okano GJ Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder Am J Manag Care 2002, 8 (19 Suppl):S608-S615. 12516955
17. Homma Y Kawabe K Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: A randomized, placebo-controlled trial World J Urol 2004, 22(4):251-256. 10.1007/s00345-004-0455-3 15455256
18. Freeman R Hill S Millard R Slack M Sutherst J Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine Obstet Gynecol 2003, 102(3):605-611. 10.1016/ S0029-7844(03)00623-9 12962951
19. Roberts R Bavendam T Glasser DB Carlsson M Eyland N Elinoff V Tolterodine extended release improves patient-reported outcomes in overactive bladder: Results from the IMPACT trial Int J Clin Pract 2006, 60:752-758. 10.1111/j.1742-1241.2006.00987.x 16805764
20. Abrams P Artibani W Gajewski JB Hussain I Assessment of treatment outcomes in patients with overactive bladder: Importance of objective and subjective measures Urology 2006, 68(suppl 2A):17-28. 10.1016/ j.urology.2006.05.044
21. van Kerrebroeck P Kreder K Jonas U Zinner N Wein A Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder Urology 2001, 57(3):414-421. 10.1016/ S0090-4295(00)01113-4 11248608
22. Kelleher CJ Cardozo LD Khullar V Salvatore S A new questionnaire to assess the quality of life of urinary incontinent women Br J Obstet Gynaecol 1997, 104(12):1374-1379. 9422015
23. Kelleher CJ Pleil AM Reese PR Burgess SM Brodish PH How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder BJOG 2004, 111(6):605-612. 15198790 10.1111/ j.1471-0528.2004.00129.x
24. Matza LS Thompson CL Krasnow J Brewster-Jordan J Zycyzynski T Coyne KS Test-retest reliability of four questionnaires for patients with overactive bladder: The Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ) Neurourol Urodyn 2005, 24:215-225. 10.1002/nau.20110 15747340
25. Cohen J Statistical Power Analysis for the Behavioral Sciences Hillsdale, NJ: Lawrence Erlbaum Associates 2 1988.
26. Homma Y Paick JS Lee JG Kawabe K Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial BJU Int 2003, 92(7):741-747. 10.1046/ j.1464-410X.2003.04468.x 14616458
27. Michel MC de la Rosette JJ Piro M Schneider T Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder Eur Urol 2005, 48(1):110-115. 10.1016/ j.eururo.2004.11.012 15967259
28. Coyne KS Elinoff V Gordon DA Deng DY Brodsky M Glasser DB Jumadilova Z Carlsson M Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine Int J Clin Pract 2008, 62(6):925-931. 10.1111/ j.1742-1241.2008.01778.x 18479285
29. Coyne KS Matza LS Thompson CL The responsiveness of the Overactive Bladder Questionnaire (OAB-q) Qual Life Res 2005, 14:849-855. 10.1007/ s11136-004-0706-1 16022077
30. Coyne K Tubaro A Brubaker L Bavendam T Development and validation of patient-reported outcomes measures for overactive bladder Urology 2006, 68(suppl 2A):9-16. 10.1016/j.urology.2006.05.042
31. Homma Y Yoshida M Seki N Yokoyama O Kakizaki H Gotoh M Yamanishi T Yamaguchi O Takeda M Nishizawa O Symptom assessment tool for overactive bladder syndrome - overactive bladder symptom score Urology 2006, 68(2):318-323. 10.1016/j.urology.2006.02.042 16904444
32. Cardozo L Coyne KS Versi E Validation of the Urgency Perception Scale BJU Int 2005, 95:591-596. 10.1111/j.1464-410X.2005.05345.x 15705086
33. Marschall-Kehrel D Roberts RG Brubaker L Patient-reported outcomes in overactive bladder: The influence of perception of condition and expectation for treatment benefit Urology 2006, 68(suppl 2A):29-37. 10.1016/j.urology.2006.02.046